ClinicalTrials.gg
RecruitingNCT07947576ICMUpdated Nov 19, 2026

Intensive Case Management for Substance Use Disorders (RCT)

An interventional study of Intensive Case Management and Treatment as Usual (TAU) in Substance Use Disorders, sponsored by Psychiatric Services Aargau AG. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Psychiatric Services Aargau AG · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2026, registered Nov 2026).
  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Substance-Related Disorders with a site in Switzerland — 6 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · Switzerland.

Planned enrollment
5th of 23
180 · median 28
Started
2026
with 1 other
No phase
14 of 27
6 open now
Registered
27th of 27
by date
Lead sponsor
1 of 27
Psychiatric Services Aargau AG

Among the 27 studies in Substance-Related Disorders with a site in Switzerland, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 with no phase, and was the 27th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

6 of the 27 studies in Substance-Related Disorders with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Substance-Related Disorders with a site in Switzerland, or all of them as a file.
02

Study summary

This study aims to assess the effectiveness of Intensive Case Management (ICM) compared to TAU. Economically, this study could contribute to more cost-effective treatments, since relatively expensive inpatient care could be relieved of patients not benefiting from inpatient care, and those patients would receive a more adequate and effective treatment. Our first goal is to evaluate the effectivenessof ICM as a treatment for people with SUDs in the canton of Aargau compared to TAU. To assess the effectiveness, the outcome measured will be the RICID and the NOIA. Furthermore, the increase in Quality of Life and Social Integration with appropriate Questionnaires of Patients in ICM is compared to Patients in TAU. The second goal of this study is to evaluate the cost-effectiveness of ICM for the aforementioned patients compared to TAU.

Case Management, especially for people with multiple and complex needs, is an intervention designed to enhance coordination and continuity of support and care (Vanderplasschen et al. 2019). Also, for people with high levels of disability due to mental illness, ICM is widely claimed to be an evidence-based and cost-effective program (King, 2006). Furthermore, key ICM components, linkage and retention, seem to show the largest effect sizes (SMD = 0.33, 95% CI 0.18-0.48) in ICM. Linkage and retention are necessary prerequisites that keep patients with SUDs in contact with health services (Vanderplasschen et al., 2019). Although evidence across all outcome measures, according to the same author, is significant and positive, but small (SMD = 0.18, 95% CI [0.07-0.28]). There is mixed evidence in outcomes such as health outcomes (SMD = -0.16, 95%CI [-0.40, 0.08]), social functioning (SMD = 0.14, 95% CI [-0.01, 0.28]) or reduced substance use (SMD = 0.10, 95% CI [-0.02, 0.21]).

Moreover, ICM and closely related models (i.e., Assertive Community Treatment, ACT) show a Reduction in Cumulative Inpatient Days (RICID) and a reduction in inpatient admissions (Dietrich et al., 2017; Burns et al., 2007). This is a common outcome in ICM literature and is also a measure for reductions in healthcare costs, since inpatient treatments are bound to high costs.

In this study, there are mainly four groups of patients with SUDs that, despite previous or present linkages to health services, do need further or a different kind of treatment. Those patients are:

  • People with low treatment satisfaction and high usage of health and social services: These patients, despite their previous treatments and social connections, do not improve sufficiently and continue to utilize healthcare services.
  • people that already are in complex helping systems and make use of a high number of treatments but show a high need for coordination to be effective
  • patients with dual diagnosis, with SUD being one of those in combination with, e.g., schizophrenia, personality disorders and anxiety disorders and would need intense and continuous care.
  • people that, due to their clinical picture or other difficulties in life, do not have access to existing treatments (anymore) and fall through the social network. It includes people without permanent addresses, people with precarious housing conditions or socially isolated people, independent of their employment status.

Sex and gender will be treated as potential covariates and will be considered in the analysis.

03

Conditions studied

  • Substance Use Disorders
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 4 or more inpatient admissions in the last 24 months
  • Diangosed SUD
  • Residence or temporary stay in the canton of Aargau

Exclusion criteria

Exclusion Criteria:

  • any emergency situation requiring psychiatric or hospital admissions
  • inability to give
  • acute, unstable psychotic symptoms
  • acute risk of harm to self or others
  • insufficient german language skills
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Experimental

    receives ICM immediately

    Other: Intensive Case Management

  • Active comparator
    Waiting List

    Same as Experimental, only with 6-Month TAU-Waiting List before ICM

    Other: Treatment as Usual (TAU)

Interventions

  • OtherIntensive Case Management

    Intensive Case Management for People with SUDs and complex psychosocial needs is an outreach-based intervention aimed at linking participants to health services and coordinating them. Additionally, two focus points are implemented to increase adherence and engagement: 1. Intensive crisis intervention: Offering immediate, flexible support in acute crises, preventing escalations early and strengthening the stability of patients. 2. Relationship continuity: Establishing an empathetic \& constant presence, breaking down barriers, creating a trustful, stable relationship.

  • OtherTreatment as Usual (TAU)

    TAU will take place for 6 months before starting with ICM

06

What researchers measure

Primary outcomes

  1. Number of Inpatient Admissions (Health Service utilisation)

    Number of Inpatient Admissions into psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

    Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

  2. Number of Inpatient Days (Health Service utilisation)

    Number of Inpatient Days in psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

    Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Secondary outcomes

  1. WHOQoL-BREF

    Quality of Life

    Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

  2. SFQ

    Social Functioning Questionnaire

    Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Other outcomes

  1. ASSIST

    Substance use characteristics

    Time frame: 6 Months (exploratory), 24 months (exploratory)

  2. Continuity of Care (Brice-Boxerman)

    Continuity of Care describes timeframes of the health services used outside the ward.

    Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

  3. Linking

    Linking describes the successful referral to health services not captured by the primary endpoint (meaning, outside the ward) and is the central mechanism of this Intensive Case Management.

    Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

  4. Retention

    Retention describes the voluntary staying of patients in the ICM treatment

    Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

  5. BSCL

    Brief Symptoms Checklist, measuring the most common somatic and psychological symptoms found in psychiatric care

    Time frame: 6 Months (exploratory), 24 months (exploratory)

  6. EQ-5D-5L

    EuroQOL Quality of Life questionnaire for assessing cost-effectiveness (Incremental cost-effectiveness ratio, ICER)

    Time frame: 6 Months (exploratory), 24 months (exploratory)

07

Study locations

1 of 1 sites recruiting
  • PDAG
    Windisch, Canton of Aargau 5210, Switzerland
    Recruiting
    • Johannes Senesi, MSc · Contactjohannes.senesi@pdag.ch · +41564622670
    • Johannes Senesi, Msc · Principal investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 36 months is close to that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartActual
Jul 4, 2026
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947576
Lead sponsor
Psychiatric Services Aargau AG
Collaborators
BZBPlus, Suchtberatung ags, Canton of Aargau
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Jul 4, 2026
Primary completion
Jul 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Johannes Senesi, MSc
Contact
johannes.senesi@pdag.ch
+41564622670

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion